Abstract：
OBJECTIVE: Breatlessness flares directly impair quality of life of patients with cancer. The aim of this review was to analyse and synthesise the available information related to its terminology, definition and clinical features in patients with cancer.
METHODS: Integrative systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Literature search was conducted in MEDLINE PubMed, CINAHLPlus, Web of Science, Cochrane Central Register Controlled Trials CENTRAL, Scopus and OpenAire.
RESULTS: Data from 1065 patients with cancer included in 12 studies were analysed. The preferred term for breathlessness flares was episodic dyspnoea (ED). The reported frequency of ED was 20.4% (70.9% in patients reporting background dyspnoea (BD)). ED intensity was moderate to severe with short duration (<10 min) in >80% of patients. The most common trigger was exertion (>90%) followed by emotional or environmental factors. ED management consisted mainly of pharmacological and non-pharmacological measures.
CONCLUSIONS: This systematic review shows that ED is common in patients with cancer, especially in those with BD. Further studies are urgently needed to better understand this condition and to develop specific therapeutic management.
UNASSIGNED: CRD42019126708.
METHODS: Integrative systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Literature search was conducted in MEDLINE PubMed, CINAHLPlus, Web of Science, Cochrane Central Register Controlled Trials CENTRAL, Scopus and OpenAire.
RESULTS: Data from 1065 patients with cancer included in 12 studies were analysed. The preferred term for breathlessness flares was episodic dyspnoea (ED). The reported frequency of ED was 20.4% (70.9% in patients reporting background dyspnoea (BD)). ED intensity was moderate to severe with short duration (<10 min) in >80% of patients. The most common trigger was exertion (>90%) followed by emotional or environmental factors. ED management consisted mainly of pharmacological and non-pharmacological measures.
CONCLUSIONS: This systematic review shows that ED is common in patients with cancer, especially in those with BD. Further studies are urgently needed to better understand this condition and to develop specific therapeutic management.
UNASSIGNED: CRD42019126708.
摘要：
目的：无呼吸耀斑直接损害癌症患者的生活质量。这次审查的目的是分析和综合与其术语有关的现有信息，癌症患者的定义和临床特征。
方法：根据系统评价和荟萃分析指南的首选报告项目进行综合系统评价。文献检索在MEDLINEPubMed进行，CINAHLPlus,WebofScience,Cochrane中央寄存器控制试验中心，Scopus和OpenAire。
结果：分析了12项研究中1065例癌症患者的数据。呼吸困难发作的首选术语是偶发性呼吸困难（ED）。报告的ED频率为20.4％（报告背景呼吸困难（BD）的患者为70.9％）。>80％的患者的ED强度为中度至重度，持续时间短（<10分钟）。最常见的触发因素是劳累（>90％），其次是情绪或环境因素。ED管理主要包括药理学和非药理学措施。
结论：本系统综述显示ED在癌症患者中很常见，尤其是那些有BD的人。迫切需要进一步的研究来更好地了解这种情况并制定具体的治疗管理。
未经评估：CRD42019126708。
方法：根据系统评价和荟萃分析指南的首选报告项目进行综合系统评价。文献检索在MEDLINEPubMed进行，CINAHLPlus,WebofScience,Cochrane中央寄存器控制试验中心，Scopus和OpenAire。
结果：分析了12项研究中1065例癌症患者的数据。呼吸困难发作的首选术语是偶发性呼吸困难（ED）。报告的ED频率为20.4％（报告背景呼吸困难（BD）的患者为70.9％）。>80％的患者的ED强度为中度至重度，持续时间短（<10分钟）。最常见的触发因素是劳累（>90％），其次是情绪或环境因素。ED管理主要包括药理学和非药理学措施。
结论：本系统综述显示ED在癌症患者中很常见，尤其是那些有BD的人。迫切需要进一步的研究来更好地了解这种情况并制定具体的治疗管理。
未经评估：CRD42019126708。
